Valuation: Gilead Sciences, Inc.

Market Cap 168B 146B 137B 125B 235B 16,057B 238B 1,601B 627B 8,037B 632B 618B 26,813B P/E 2026 *
-42.2x
P/E 2027 * 17x
Enterprise Value 185B 160B 150B 137B 258B 17,654B 262B 1,761B 690B 8,836B 695B 680B 29,480B EV / Sales 2026 *
6.03x
EV / Sales 2027 * 5.43x
Free-Float
99.88%
Yield 2026 *
2.43%
Yield 2027 * 2.51%
1 day+0.52%
1 week+2.61%
Current month+2.92%
1 month+1.31%
3 months+2.05%
6 months-11.47%
Current year+9.65%
1 week 112.64
Extreme 112.64
116.36
1 month 112.3
Extreme 112.3
120.86
Current year 99.98
Extreme 99.98
131.64
1 year 92.6
Extreme 92.6
131.64
3 years 57.55
Extreme 57.55
131.64
5 years 52.24
Extreme 52.24
131.64
10 years 46.24
Extreme 46.245
131.64
Manager TitleAgeSince
Chief Executive Officer 61 28/02/2019
Director of Finance/CFO 56 31/10/2019
Compliance Officer - 17/12/2025
Director TitleAgeSince
Director/Board Member 58 18/08/2016
Director/Board Member 73 31/12/2017
Director/Board Member 72 08/05/2018
Change 5-day change 1-year change 3-year change Capi.($)
+0.52%+2.61% - - 165B
-1.37%+8.90%+91.28%+130.00% 1,098B
-0.77%+1.91%+49.46%+49.44% 631B
+0.85%+2.58%+25.90%+64.34% 438B
-1.13%+3.13%+49.78%+39.13% 368B
-0.74%+1.01%+31.08%+38.64% 298B
-1.22%+0.89%+7.32%+7.38% 251B
-0.70%+6.23%+45.32%+57.82% 226B
+0.34%-0.13%-4.77%-50.50% 209B
+2.04%+0.38%+12.70%+69.71% 165B
Average -0.22%+1,662.58%+34.23%+45.11% 409.37B
Weighted average by Cap. -0.58%+1,339.54%+49.81%+66.19%

Financials

2026 *2027 *
Net sales 30.69B 26.6B 24.9B 22.72B 42.75B 2,927B 43.47B 292B 114B 1,465B 115B 113B 4,888B 32.67B 28.31B 26.51B 24.19B 45.51B 3,116B 46.28B 311B 122B 1,560B 123B 120B 5,204B
Net income -4.16B -3.61B -3.38B -3.08B -5.8B -397B -5.9B -39.62B -15.52B -199B -15.64B -15.3B -663B 10.21B 8.85B 8.28B 7.56B 14.22B 974B 14.46B 97.12B 38.05B 487B 38.33B 37.5B 1,626B
Net Debt 16.75B 14.51B 13.59B 12.4B 23.33B 1,597B 23.72B 159B 62.41B 799B 62.87B 61.5B 2,667B 9.12B 7.91B 7.4B 6.75B 12.71B 870B 12.92B 86.8B 34.01B 436B 34.26B 33.51B 1,453B
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
11/08/26 €116.36 +0.52% 14
10/08/26 €115.76 +0.14% 182
07/08/26 €115.60 +2.63% 284
06/08/26 €112.64 -0.02% 103
05/08/26 €112.66 -0.65% 454
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
135.77USD
Average target price
157.41USD
Spread / Average Target
+15.94%

Quarterly revenue - Rate of surprise